SciClone Pharmaceuticals News
SciClone Pharmaceuticals, Inc. today reported its expectations regarding financial results for the quarter ended March 31, 2013.
SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China MarketMarketwired May 16
SciClone Pharmaceuticals, Inc. today announced that the Company has entered into an agreement with Zensun Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong ...
Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert Portfolio Manager Finny Kuruvilla Discusses His Construction Strategy with The Wall Street TranscriptMay 16
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations anMay 16
Emerging Markets an Area of Opportunity for Global Generic Players: An Expert Analyst Gives His Take on the Generic Drug SpaceMay 2
FOSTER CITY, CA -- (Marketwired) -- 04/08/13 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers ...